|
Release Date
December 23, 2009
|
Expiration Date
December 23, 2010 |
|
|
| Faculty |
Harold J. Burstein, MD, PhD
Dana-Farber Cancer Institute
Boston, Massachusetts |
William J. Gradishar, MD, FACP
Northwestern University
Chicago, Illinois
|
Mohammad Jahanzeb, MD
Aptium Oncology
Boca Raton, Florida
|
Stephen E. Jones, MD
US Oncology
Dallas, Texas
|
|
Lee Lokey, MD
prIME Oncology
Atlanta, Georgia
|
Mark Pegram, MD
University of Miami
Sylvester Comprehensive Cancer Center
Miami, Florida
|
Sunil Verma, MD, MSEd, FRCPC
University of Toronto
Toronto, Ontario, Canada
|
Giuseppe Viale, MD, PhD
University of Milan School of Medicine
Milan, Italy
|
Target Audience
This educational activity is intended for medical oncologists, surgical oncologists, breasts surgeons, and other healthcare professionals interested in or involved in the care of patients with breast cancer. |
Overview
These interviews are regarding recently released data from San Antonio Breast Cancer Symposium, focusing on various aspects of the management of patients with breast cancer. |
Educational Objectives
Upon completion of this educational activity, participants should be able to:
- Select optimal adjuvant and neoadjuvant treatment regimens for patients with breast cancer
- Evaluate data from recent clinical trials regarding the selection of appropriate treatment regimens for patients with endocrine-responsive breast cancer
- Discuss the role of prognostic and predictive tools in risk assessment and treatment planning for patients with breast cancer
- Describe the emerging role of targeted agents in both adjuvant and metastatic breast cancer treatment
- Identify new agents for the management of metastatic breast cancer
|
Sponsorship Statement
This activity is jointly sponsored by Indiana University School of Medicine and prIME Oncology. |
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Indiana University School of Medicine (IUSM) and prIME Oncology. Indiana University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians. |
Credit Designation Statement
Indiana University School of Medicine designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. |
Method of Participation
There are no fees for participating in and receiving CME credit for this activity, In order to receive credit, participants must successfully complete the online post test and activity evaluation. Your participation in this CME activity will be recorded in Indiana University School of Medicine's database. However, upon request, your CME credit certificate will be e-mailed to you.
You may complete the post-test online at:http://cme.medicine.iu.edu/forms/Interviews.aspx |
Support Statement
This activity is supported by educational grants from Genentech BioOncology; Novartis Oncology; Pfizer Inc.; and sanofi-aventis. |
Disclosure of Conflicts of Interest
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Indiana University School of Medicine must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, and planning committee members participating in an IUSM-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
Dr Burstein has disclosed that he has no real or apparent conflicts of interest to report and no relevant financial relationships with any commercial interests.
Dr Gradishar has disclosed that he has received consulting fees from AstraZeneca Pharmaceuticals LP and Novartis Pharmaceuticals Corporation. None of these relationships will impact his ability to present an unbiased discussion.
Dr Jahanzeb has disclosed that he has received grant and research support from Genentech BioOncology; Pfizer Inc; and Oxigene, Inc. He has also served on speakers’ bureaus for Abraxis Oncology; AstraZeneca Pharmaceuticals LP; Genentech BioOncology; GlaxoSmithKline; Roche Laboratories Inc.; and sanofi-aventis. In addition, he has served on advisory boards for Abraxis Oncology; AstraZeneca Pharmaceuticals LP; Bayer HealthCare Corporation; Bristol-Myers Squibb Company; Eisai Inc.; Eli Lilly and Company; Genentech BioOncology; GlaxoSmithKline; ImClone Systems Incorporated; Novartis Oncology; Onyx Pharmaceuticals Inc.; Oxigene, Inc.; Pfizer Inc; and sanofi-aventis. None of these relationships will impact his ability to present an unbiased discussion.
Dr Jones has disclosed that he has received honoraria and consulting fees and served on speakers’ bureaus and advisory boards for AstraZeneca Pharmaceuticals LP; Genentech BioOncology; GlaxoSmithKline; Pfizer Inc; and sanofi-aventis. None of these relationships will impact his ability to present an unbiased discussion.
Dr Lokey has disclosed that he has no real or apparent conflicts of interest to report and no relevant financial relationships with any commercial interests.
Dr Pegram has disclosed that he has received consulting fees from Genentech BioOncology, GlaxoSmithKline, sanofi-aventis, and Takeda San Francisco, Inc. None of these relationships will impact his ability to present an unbiased discussion.
Dr Viale has disclosed that he has received honoraria for lecturing and serving on advisory boards from Agendia; Boehringer Ingelheim Pharmaceuticals, Inc.; GlaxoSmithKline; Novartis Oncology; and Roche Laboratories Inc. None of these relationships will impact his ability to present an unbiased discussion.
Dr Verma has disclosed that he has received honoraria and speaker’s fees from Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Roche Laboratories Inc.; and sanofi-aventis. None of these relationships will impact his ability to present an unbiased discussion.
The employees of prIME Oncology have disclosed:
- Michael Checkoway (project management) – no real or apparent conflicts of interest
- Kathryn Charalambous, PhD (editorial) – no real or apparent conflicts of interest
- Trudy Stoddert, ELS (editorial) – no real or apparent conflicts of interest
|
Disclosure of Unlabeled Use
This educational activity may contain discussion of published or and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Indiana University School of Medicine, prIME Oncology, and the supporters of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of IUSM or prIME Oncology. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
While it offers CME credits, this activity is not intended to provide extensive training or certification in the field.
|
